



Attorney Docket No.: 5956.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: 09/662,457

Group Art Unit: To be assigned

Filed: September 11, 2000

Examiner: To be assigned

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 99/46267;
2. WO 99/46237;
3. WO 99/46268;
4. U.S. Patent 3,953,468;
5. United Kingdom Patent 1 583 679;


6. Iversen et al., The Journal of Biological Chemistry, Vol. 275, pgs. 10300-10307 (2000); and
7. Peters et al., The Journal of Biological Chemistry, Vol. 275, pgs. 18201-18209 (2000).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: March 28, 2001



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Serial No. 09/662,457

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant Andersen et al.

(Use several sheets if necessary)

Filing Date September 11, 2000

Group To be assigned

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.